Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Determining the Maximal Safe Dose of a Continuous Infusion of Parathyroid Hormone-related Protein(1-36): Effects on Bone Formation

NCT00580788 is registered in ClinicalTrials.gov with University of Pittsburgh as lead sponsor.

NCT NCT00580788
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00580788 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Determining the Maximal Safe Dose of a Continuous Infusion of Parathyroid Hormone-related Protein(1-36): Effects on Bone Formation
Lead sponsor
University of Pittsburgh
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2008
Completion date
December 31, 2009
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

humoral hypercalcemia of malignancy, hyperparathyroidism, osteoporosis